Conflict of interest statement. Under a licensing agreement between Geron Corporation and Johns Hopkins University, Dr. Shamblott is entitled to a share of royalty received by the University on sales of products described in this article. Dr. Shamblott and the university own Geron stock, which is subject to certain restrictions under University policy. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
1520-7560/asset/bannerforeground.jpg?v=1&s=97ddd213ca98f827538987e02b801875335d1a52)
Review Article
Glucose-responsive insulin-producing cells from stem cells
Article first published online: 17 OCT 2002
DOI: 10.1002/dmrr.330
Copyright © 2002 John Wiley & Sons, Ltd.
Issue
1520-7560/asset/cover.gif?v=1&s=518ef24df4af0f53197d5b36e1afedd4421360a2 "Diabetes/Metabolism Research and Reviews")
Diabetes/Metabolism Research and Reviews
Volume 18, Issue 6, pages 442–450, November/December 2002
Additional Information
How to Cite
Kaczorowski, D. J., Patterson, E. S., Jastromb, W. E. and Shamblott, M. J. (2002), Glucose-responsive insulin-producing cells from stem cells. Diabetes Metab. Res. Rev., 18: 442–450. doi: 10.1002/dmrr.330
- †
Conflict of interest statement. Under a licensing agreement between Geron Corporation and Johns Hopkins University, Dr. Shamblott is entitled to a share of royalty received by the University on sales of products described in this article. Dr. Shamblott and the university own Geron stock, which is subject to certain restrictions under University policy. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
Publication History
- Issue published online: 4 DEC 2002
- Article first published online: 17 OCT 2002
- Manuscript Accepted: 2 AUG 2002
- Manuscript Revised: 25 JUL 2002
- Manuscript Received: 3 JUN 2002
- Abstract
- Article
- References
- Cited By
Keywords:
- diabetes;
- transplantation;
- stem;
- embryonic;
- germ
Abstract
Recent success with immunosuppression following islet cell transplantation offers hope that a cell transplantation treatment for type 1 (juvenile) diabetes may be possible if sufficient quantities of safe and effective cells can be produced. For the treatment of type 1 diabetes, the two therapeutically essential functions are the ability to monitor blood glucose levels and the production of corresponding and sufficient levels of mature insulin to maintain glycemic control. Stem cells can replicate themselves and produce cells that take on more specialized functions. If a source of stem cells capable of yielding glucose-responsive insulin-producing (GRIP) cells can be identified, then transplantation-based treatment for type 1 diabetes may become widely available. Currently, stem cells from embryonic and adult sources are being investigated for their ability to proliferate and differentiate into cells with GRIP function. Human embryonic pluripotent stem cells, commonly referred to as embryonic stem (ES) cells and embryonic germ (EG) cells, have received significant attention owing to their broad capacity to differentiate and ability to proliferate well in culture. Their application to diabetes research is of particular promise, as it has been demonstrated that mouse ES cells are capable of producing cells able to normalize glucose levels of diabetic mice, and human ES cells can differentiate into cells capable of insulin production. Cells with GRIP function have also been derived from stem cells residing in adult organisms, here referred to as endogenous stem cell sources. Independent of source, stem cells capable of producing cells with GRIP function may provide a widely available cell transplantation treatment for type 1 diabetes. Copyright © 2002 John Wiley & Sons, Ltd.